M&A / Acquisition · MENA · Announced 17 Jun 2026
Laprophan → Rivopharm
Moroccan drugmaker Laprophan completed its first European acquisition, taking 60% of Swiss generics developer and manufacturer Rivopharm and two related companies alongside founder Piero Poli; Rivopharm has about US$100m in annual revenue.
Parties: Laprophan (Morocco) → Rivopharm (Switzerland)
- Deal type
- M&A / Acquisition
- Value
- Undisclosed
- Territory
- Europe (Switzerland, Ireland, Netherlands; Rivopharm sells in 30+ countries)
- Therapeutic area
- Multi-therapy
- Assets
- Rivopharm; Double-e Pharma; Pian Holding
- Announced
- 17 Jun 2026
Our analysis
Why this matters
Laprophan Group completed its first European acquisition on 17 June 2026. Through Europhan Europe SA, its Luxembourg-based European platform, it took 60% stakes in three linked companies: Rivopharm, Double-e Pharma and the Dutch holding Pian Holding BV. It did so alongside Rivopharm's historical shareholder, Swiss investor Piero Poli, who keeps a significant minority stake and shares governance. The deal was first announced in October 2025 and notified to Morocco's Competition Council. Financial terms were not disclosed.
Rivopharm develops and manufactures generics and complex formulations at its own industrial site in Lugano, Switzerland, and licenses dossiers to generics companies. It reports about US$100 million in annual revenue, around 125 molecules and 1,500 product references, and sales in more than 30 countries. Its subsidiaries include Rivopharm UK, Holsten Pharma (Germany) and Sanoswiss (Lithuania). Reports differ on where Rivopharm Limited is registered: Ireland in one report, Switzerland in others.
The full analysis is free to read with a work email on this page.
Source: Le Matin